Bird Flu Market Size, Share & Trends Analysis Report By Virus Type (H5N1, H7N9, H5N6, H5N8, H10N8, H9N2, Others), By Test Type (PCR Tests, ELISA Tests, Hemagglutination Assays, Virus Isolation Tests, Next Generation Sequencing, Others), By Treatment Type, By Animal Type, By Region, And By Segment Forecasts, 2024-2031
Segmentation of The Bird Flu Market
The Bird Flu Market By Virus Type:
- H5N1
- H7N9
- H5N6
- H5N8
- H10N8
- H9N2
- Others
The Bird Flu Market By Test Type:
- PCR Tests
- ELISA Tests
- Hemagglutination Assays
- Virus Isolation Tests
- Next Generation Sequencing
- Others
The Bird Flu Market By Treatment and Prevention Type:
- Vaccines
- Antiviral Medication
- Immunomodulators
- POPE
- PAPER
The Bird Flu Market By Animal Type:
- Chickens
- Ducks
- Geese & Swans
- Pigeons
- Guinea Fowls
- Turkeys
- Others
The Bird Flu Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Bird Flu Market Snapshot
Chapter 4. Global Bird Flu Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Virus Type Estimates & Trend Analysis
5.1. by Virus Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Virus Type:
5.2.1. H5N1
5.2.2. H7N9
5.2.3. H5N6
5.2.4. H5N8
5.2.5. H10N8
5.2.6. H9N2
5.2.7. Others
Chapter 6. Market Segmentation 2: by Test Type Estimates & Trend Analysis
6.1. by Test Type & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Test Type:
6.2.1. PCR Tests
6.2.2. ELISA Tests
6.2.3. Hemagglutination Assays
6.2.4. Virus Isolation Tests
6.2.5. Next Generation Sequencing
6.2.6. Others
Chapter 7. Market Segmentation 3: by Treatment Type Estimates & Trend Analysis
7.1. by Treatment Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment Type:
7.2.1. Vaccines
7.2.2. Antiviral Medication
7.2.3. Immunomodulators
7.2.4. Others
Chapter 8. Market Segmentation 4: by Animal Type Estimates & Trend Analysis
8.1. by Animal Type & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Animal Type;
8.2.1. Chickens
8.2.2. Ducks
8.2.3. Geese & Swans
8.2.4. Pigeons
8.2.5. Guinea Fowls
8.2.6. Turkeys
8.2.7. Others
Chapter 9. Bird Flu Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Virus Type, 2019-2031
9.1.2. North America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2019-2031
9.1.3. North America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.1.4. North America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2019-2031
9.1.5. North America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Virus Type,2019-2031
9.2.2. Europe Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2019-2031
9.2.3. Europe Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.2.4. Europe Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2019-2031
9.2.5. Europe Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Virus Type, 2019-2031
9.3.2. Asia Pacific Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2019-2031
9.3.3. Asia-Pacific Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.3.4. Asia Pacific Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Animal Type ,2019-2031
9.3.5. Asia Pacific Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Virus Type, 2019-2031
9.4.2. Latin America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2019-2031
9.4.3. Latin America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.4.4. Latin America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2019-2031
9.4.5. Latin America Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Virus Type, 2019-2031
9.5.2. Middle East & Africa Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Test Type, 2019-2031
9.5.3. Middle East & Africa Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.5.4. Middle East & Africa Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by Animal Type, 2019-2031
9.5.5. Middle East & Africa Bird Flu Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Boehringer Ingelheim
10.2.2. Ceva Santé Animale
10.2.3. Zoetis
10.2.4. Merck & Co.
10.2.5. Ringpu Biology
10.2.6. Yebio Bioengineering
10.2.7. FATRO
10.2.8. CAVAC
10.2.9. ChengDu Tecbond
10.2.10. QYH Biotech
10.2.11. Elanco
10.2.12. Phibro Animal Health
10.2.13. Vetoquinol
10.2.14. Hipra
10.2.15. Venkys
10.2.16. Anicon Labor GmbH
10.2.17. Medion Farma Jaya
10.2.18. Bioveta
10.2.19. Lohmann Animal Health
10.2.20. Biogenesis Bago
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Bird Flu Market Size is valued at USD 1.41 Bn in 2023 and is predicted to reach USD 2.17 Bn by the year 2031
Bird Flu Market is expected to grow at a 5.82% CAGR during the forecast period for 2024-2031.
Elanco, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, AstraZeneca, Johnson & Johnson Private Limited, Bimeda, Inc., Phibro Animal